[go: up one dir, main page]

DE69131069D1 - Plasmid das für die aminosäuresequenz von tcf-ii kodierende dns enthalt, transformierte zelle und produktion einer physiologisch aktiven substanz mit ihrer verwendung - Google Patents

Plasmid das für die aminosäuresequenz von tcf-ii kodierende dns enthalt, transformierte zelle und produktion einer physiologisch aktiven substanz mit ihrer verwendung

Info

Publication number
DE69131069D1
DE69131069D1 DE69131069T DE69131069T DE69131069D1 DE 69131069 D1 DE69131069 D1 DE 69131069D1 DE 69131069 T DE69131069 T DE 69131069T DE 69131069 T DE69131069 T DE 69131069T DE 69131069 D1 DE69131069 D1 DE 69131069D1
Authority
DE
Germany
Prior art keywords
tcf
cdna
amino acid
plasmid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69131069T
Other languages
English (en)
Other versions
DE69131069T2 (de
Inventor
Nobuyuki Shima
Kanji Higashio
Masaya Nagao
Fumiko Oogaki
Hiroaki Takaoka
Eisuke Tsuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atlas Pharmaceuticals Inc Sunnyvale Calif Us
Original Assignee
Snow Brand Milk Products Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Snow Brand Milk Products Co Ltd filed Critical Snow Brand Milk Products Co Ltd
Application granted granted Critical
Publication of DE69131069D1 publication Critical patent/DE69131069D1/de
Publication of DE69131069T2 publication Critical patent/DE69131069T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
DE69131069T 1990-07-13 1991-07-15 Plasmid das für die aminosäuresequenz von tcf-ii kodierende dns enthalt, transformierte zelle und produktion einer physiologisch aktiven substanz mit ihrer verwendung Expired - Fee Related DE69131069T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP18585290 1990-07-13
PCT/JP1991/000942 WO1992001053A1 (fr) 1990-07-13 1991-07-15 Plasmide contenant l'adn qui code pour la sequence d'acides amines du facteur tcf-ii, cellules transformees par ce plasmide et production d'une substance physiologiquement active grace a l'utilisation de ce plasmide

Publications (2)

Publication Number Publication Date
DE69131069D1 true DE69131069D1 (de) 1999-05-06
DE69131069T2 DE69131069T2 (de) 1999-07-15

Family

ID=16178009

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69131069T Expired - Fee Related DE69131069T2 (de) 1990-07-13 1991-07-15 Plasmid das für die aminosäuresequenz von tcf-ii kodierende dns enthalt, transformierte zelle und produktion einer physiologisch aktiven substanz mit ihrer verwendung

Country Status (10)

Country Link
US (1) US5328836A (de)
EP (1) EP0539590B1 (de)
JP (1) JP2634323B2 (de)
KR (1) KR0153009B1 (de)
AT (1) ATE178354T1 (de)
CA (1) CA2066618C (de)
DE (1) DE69131069T2 (de)
DK (1) DK0539590T3 (de)
ES (1) ES2132087T3 (de)
WO (1) WO1992001053A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ232813A (en) * 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
US5821223A (en) * 1990-09-14 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating cell growth with a novel broad spectrum human lung fibroblast-derived mitogen
JP3395181B2 (ja) * 1991-07-26 2003-04-07 東レ株式会社 造血幹細胞増加剤
CA2118012A1 (en) * 1992-05-18 1993-11-25 Paul J. Godowski Hepatocyte growth factor variants
US5328837A (en) * 1992-05-18 1994-07-12 Genentech, Inc. Hepatocyte growth factor protease domain variants
US5316921A (en) * 1992-05-18 1994-05-31 Genentech, Inc. Single-chain hepatocyte growth factor variants
DK0821969T3 (da) * 1992-07-16 2007-03-26 Daiichi Seiyaku Co Medicinsk sammensætning omfattende TCF-II
CA2140010C (en) * 1992-07-16 2008-04-01 Hiroaki Masunaga Blood coagulation normalizer containing tcf-ii as active ingredient
JP3402476B2 (ja) * 1992-08-24 2003-05-06 生化学工業株式会社 リポ多糖結合性タンパク質及びその製造法
JP3552240B2 (ja) * 1993-02-23 2004-08-11 第一製薬株式会社 高濃度ｔｃｆ製剤
IT1271088B (it) * 1994-11-24 1997-05-26 Dompe Spa Uso di fattore di crescita degli epatociti per indurre la proliferazione e differenziazione di cellule emopoietiche
EP0757994B1 (de) * 1994-12-27 2003-09-03 Daiichi Pharmaceutical Co., Ltd. Tcf mutante
KR19980020025A (ko) * 1996-09-05 1998-06-25 김종진 미생물을 이용한 폐수중의 나프탈렌 제거 방법
JP4006058B2 (ja) 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
DK0950416T3 (da) * 1997-03-14 2007-02-26 Daiichi Seiyaku Co Anvendelse af TCF-II til behandling af cancerrelateret tab af kropsvægt, anæmi og TNF-forhöjelse
KR100562824B1 (ko) 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
EP1814575A4 (de) * 2004-11-24 2010-07-07 Neopro Labs Llc Verfahren und zusammensetzungen zur behandlung von leiden
CA2647835A1 (en) * 2006-03-28 2007-10-04 Neopro Labs, Llc Methods and compositions for treating conditions
EP2152725A1 (de) 2007-05-17 2010-02-17 Neopro Labs, LLC Kristalline und amorphe peptidformen
WO2009012472A2 (en) * 2007-07-18 2009-01-22 Neopro Labs, Llc Methods and compositions for treating conditions
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
BRPI0911511B8 (pt) * 2008-04-09 2021-05-25 Helixmith Co Ltd formulação de dna liofilizadas para aumentar a expressão de dna de plasmídeo
CA2926607C (en) 2013-10-22 2018-10-23 Viromed Co., Ltd. Composition for preventing or treating amyotrophic lateral sclerosis using two or more isoforms of hepatocyte growth factor
EP3823677A4 (de) 2018-07-19 2022-06-01 Helixmith Co., Ltd. Lyophilisierte pharmazeutische zusammensetzungen für nackte dna-gentherapie

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62171696A (ja) * 1986-01-23 1987-07-28 Sumitomo Chem Co Ltd ヒトエリスロポエチンの製造方法
NZ232813A (en) * 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
CA2022752C (en) * 1989-08-11 1998-07-07 Naomi Kitamura Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor
JP2777678B2 (ja) * 1990-06-11 1998-07-23 敏一 中村 組換ヒト肝実質細胞増殖因子及びその製造方法

Also Published As

Publication number Publication date
DK0539590T3 (da) 1999-10-11
US5328836A (en) 1994-07-12
ATE178354T1 (de) 1999-04-15
KR920702417A (ko) 1992-09-04
DE69131069T2 (de) 1999-07-15
CA2066618C (en) 1998-05-19
CA2066618A1 (en) 1992-01-14
JP2634323B2 (ja) 1997-07-23
EP0539590A4 (de) 1995-05-24
KR0153009B1 (ko) 1998-10-15
EP0539590A1 (de) 1993-05-05
EP0539590B1 (de) 1999-03-31
WO1992001053A1 (fr) 1992-01-23
ES2132087T3 (es) 1999-08-16

Similar Documents

Publication Publication Date Title
DE69131069D1 (de) Plasmid das für die aminosäuresequenz von tcf-ii kodierende dns enthalt, transformierte zelle und produktion einer physiologisch aktiven substanz mit ihrer verwendung
UA39161C2 (uk) Рекомбінантний білок gm-csf для збільшення продукції гранулоцитів і макрофагів у пацієнтів, вектор і кднк, що його кодують
AU638010B2 (en) Expression of biologically active platelet derived growth factor analogs in eucaryotic cells
EP0205564A4 (de) Herstellungsverfahren für erythropoietin.
BR9710665A (pt) Compostos que promovem o desenvolvimento do tecido
ATE188736T1 (de) Endothelin-dna und verwendung davon
ATE78055T1 (de) Verfahren zur herstellung von proteinen und transformierten zellen und dna-konstruktionen zur korrektur von mankos und wirtszellen sowie deren herstellung und verwendung.
EP0161640A3 (de) Mit "Vogelretrovirus-Rinderwachstumshormon"-DNS transformierte eingekapselte Mausezellen und Verfahren zum Verabreichen von BGH in vivo
ATE121776T1 (de) Expression des biologisch aktiven faktors xiii.
DE3584579D1 (de) Herstellung von polypeptiden mit human-gammainterferon-aktivitaet.
ATE93272T1 (de) Expression von protein c.
AU601959B2 (en) GM-CSF protein, its derivatives, the preparation of proteins of this type, and their use
ES548998A0 (es) Un procedimiento para producir un polipeptido
AU7681687A (en) Expression of platelet-derived growth factor and analogues
ATE48230T1 (de) Verwendung einer kombination aus tetrahydrobiopterinen und lymphokinen zur herstellung eines arzneimittels mit gesteigerter in vivo und in vitro lymphokin-aktivitaet.
DE68924222D1 (de) Megakaryocytopoietin, seine Herstellung und Benutzung.
ATE119938T1 (de) Produktion von menschlichen nervenwachstumsfaktoren.
ES2039390T3 (es) Un procedimiento para producir un factor de diferenciacion de celulas b humanas.
ATE87977T1 (de) Herstellung menschlichen somatomedins c.
ATA435083A (de) Das polypeptid interleukin-2 kodierendes gen, rekombinante, dieses gen enthaltende dna, diese rekombinante dna aufweisende zellinien und verfahren zur herstellung von interleukin-2 unter verwendung der genannten zellen
DE19920004C1 (de) Neuer zellulärer Regulationsfaktor TTO 20
WILLIS IN VITRO STIMULATION OF COLLAGEN SYNTHESIS BY PURIFIED SOMATOMEDIN IN CHONDROSARCOMA CHONDROCYTES.
MX9707244A (es) Expresion de genes en celulas de mamifero.
ATE65682T1 (de) Einstichelektrodenanordnung zur kontinuierlichen po 2?-messung im lebenden hautgewebe.
TH3929A (th) โพลีเพปไทด์ของคนที่ออกฤทธิ์ทางสรีรวิทยาชนิดที่เป็นสารใหม่สารใหม่

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: DAIICHI PHARMACEUTICAL CO., LTD., TOKIO/TOKYO, JP

8327 Change in the person/name/address of the patent owner

Owner name: ATLAS PHARMACEUTICALS, INC., SUNNYVALE, CALIF., US

8339 Ceased/non-payment of the annual fee